Asset
Zabilugene Almadenorepvec
Theriva Biologics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02045589 | phase1 | completed | 2014-01-01 | 2016-10-01 | Theriva Biologics SL | A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer |
| NCT02045602 | phase1 | completed | 2014-01-01 | 2019-05-01 | Theriva Biologics SL | Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors |
| NCT05673811 | phase2 | completed | 2023-01-10 | 2025-03-28 | Theriva Biologics SL | Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer |
FDA applications (0)
This company has no applications containing this asset.